In This Section
PRRT Indications Guidelines: Who to Treat
Event Details:
PRRT Indications Guidelines: Who to Treat
Date: Thursday, September 5, 2019
Time: 2:00 pm ET
Speaker: Thomas Hope, MD and Jonathan Strosberg, MD
Fee: Free and a collaboration between SNMMI & NANETS
Credit type/Info: AMA, SAM, VOICE
Register.
In this one-hour, complimentary webinar, join Thomas Hope, MD, University of California, San Francisco; and Jonathan Strosberg, MD, Moffitt Cancer Center present on the new peptide receptor radionuclide therapy (PRRT) procedure standards that will help improve the quality of service to patients.
With access to PRRT on the rise, representatives from the North American Neuroendocrine Tumor Society (NANETS) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) have collaborated to develop a practical consensus guideline for the administration of Lu-DOTATATE. As part of this collaboration, NANETS and SNMMI are jointly presenting a three-part series of PRRT training webinars.
Learning Objectives:
- Understand where 177Lutetium-dotatate might fit within the neuroendocrine tumor treatment landscape
- Understand impact of PRRT on key endpoints including progression-free survival and health-related quality of life
- Identify potential risks of 177Lutetium-dotatate, including long-term myelotoxicity
- Discuss relative and absolute contraindications to treatment
A Collaboration between:
 |
 |